Table 1.
Survey Responses Pertaining to Demographics, IBD History, and COVID-19 Vaccination
| Survey items | Local (n = 236) % (fraction) |
Social media (n = 670) % (fraction) |
|---|---|---|
| 1. IBD diagnosis | ||
| Crohn’s disease | 59.8 (141/236) | 48.4 (324/670) |
| Ulcerative colitis | 33.9 (80/236) | 50.2 (336/670) |
| Indeterminate colitis | 6.4 (12/236) | 1.5 (10/670) |
| 2. Race | ||
| White | 96.2 (227/236) | 92.4 (619/670) |
| Black or African American | 0.9 (2/236) | 1.6 (11/670) |
| Asian, Pacific Islander, or Native Hawaiian | 3.0 (7/236) | 5.7 (38/670) |
| Native American or Alaska Native | 0.0 (0/236) | 0.3 (2/670) |
| 3. Hispanic ethnicity | 0.4 (1/236) | 3.8 (26/670) |
| 4. Female sex | 75.4 (178/236) | 86.7 (581/670) |
| 5. Age ≥50 y | 43.2 (102/236) | 21.2 (142/670) |
| 6. IBD duration ≥10 y | 73.7 (174/236) | 52.8 (354/670) |
| 7. Level of education | ||
| No high school degree to associate’s degree | 11.9 (28/236) | 45.6 (212/670) |
| Bachelor’s degree or master’s degree | 71.2 (168/236) | 59.6 (399/670) |
| Professional or doctorate degree | 16.9 (40/236) | 8.8 (59/670) |
| 8. Tested positive for COVID-19 at any point | 3.4 (8/236) | 6.9 (46/670) |
| 9. Current IBD medicationsa | ||
| Anti-TNF | 34.8 (82/236) | 45.9 (214/670) |
| Vedolizumab or natalizumab | 16.5 (39/236) | 23.3 (156/670) |
| Tofacitinib or ustekinumab | 14.8 (35/236) | 15.2 (102/670) |
| Azathioprine, 6-mercaptopurine, or methotrexate | 11.4 (27/236) | 17.8 (119/670) |
| Mesalamine | 23.3 (55/236) | 28.8 (193/670) |
| Prednisone or oral budesonide | 3.8 (9/236) | 12.5 (84/670) |
| 10. Prior exposure to 2 or more biologic therapies | 19.1 (45/236) | 24.5 (164/670) |
| 11. Prior bowel resection surgery | 34.3 (81/236) | 23.7 (159/670) |
| 12. Received or intend to receive influenza vaccine | 92.0 (217/236) | 76.3 (511/670) |
| 13. Intention to receive COVID-19 vaccine | ||
| 1. Yes, as soon as it is available | 80.9 (191/236) | 60.0 (402/670) |
| 2. Not right away, but likely later in the year | 7.2 (17/236) | 14.0 (94/670) |
| 3. Undecided | 11.0 (26/236) | 17.3 (116/670) |
| 4. No | 0.9 (2/236) | 8.7 (58/670) |
| 14. Reasons for COVID-19 vaccination hesitancy (responses 2–4 to item #13)a | ||
| Concerned about adverse reaction to vaccine | 37.8 (17/45) | 45.5 (122/268) |
| Concerned vaccine will interfere with IBD medication efficacy | 26.7 (12/45) | 26.9 (72/268) |
| Concerned that IBD medication may render vaccine ineffective | 8.9 (4/45) | 19.8 (53/268) |
| Already had COVID-19 infection | 2.2 (1/45) | 5.6 (15/268) |
| Negative experience with last vaccine | 4.4 (2/45) | 7.8 (21/268) |
| Do not take vaccines in general | 6.7 (3/45) | 15.3 (41/268) |
| Concerned that long-term safety of vaccines is unknown | 64.4 (29/45) | 70.1 (188/268) |
| Concerned that vaccine did not undergo typical scrutiny and safety checks | 33.3 (15/45) | 41.0 (110/268) |
| Personal history of allergic reactions | 22.2 (10/45) | 18.7 (50/268) |
| Prefer to see how others tolerate vaccine first | 62.2 (28/45) | 55.6 (149/268) |
IBD, inflammatory bowel disease; TNF, tumor necrosis factor.
a
Respondents could choose multiple options for survey items #9 and #14.